MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call summary highlights strong financial performance, with significant revenue growth driven by Afrezza and FUROSCIX. Product development is advancing, with promising pipeline updates and strategic initiatives. Market strategy and shareholder return plans are not explicitly detailed but implied through growth projections. The Q&A session reveals optimism for future revenue growth, particularly with the pediatric segment and FUROSCIX auto-injector launch. Despite some management vagueness, the overall sentiment is positive, with potential catalysts for stock price appreciation. Considering the small-cap nature, a positive stock price movement (2% to 8%) is expected.

Key Financial Performance

Total Revenue for 2025 $349 million, up 22% year-over-year. Growth driven by Afrezza and FUROSCIX.

Q4 2025 Revenue $112 million, up 46% year-over-year. Record quarterly revenue.

FUROSCIX Q4 2025 Net Sales $23.3 million, up 91% year-over-year. Growth attributed to increased unit shipments and strategic initiatives.

FUROSCIX Full Year 2025 Net Sales $70.4 million, up 93% year-over-year. Growth due to consistent performance and acceleration in 2025.

Afrezza Q4 2025 Net U.S. Sales $22.3 million, up 22% year-over-year. Growth supported by first commercial shipment to Cipla for India.

Afrezza Full Year 2025 Global Net Sales $74.6 million, up 16% year-over-year. Growth driven by international expansion and profitability management.

Tyvaso DPI Manufacturing Revenues for 2025 Approximately $100 million. Provides predictable revenue due to revised supply agreement.

Royalty Revenue for Q4 2025 $34 million, up 24% year-over-year. Reflects strong performance of Tyvaso DPI.

Royalty Revenue for Full Year 2025 $128 million, up 25% year-over-year. Driven by Tyvaso DPI performance.

GAAP Net Loss for Q4 2025 $15.9 million. Loss attributed to acquisition-related expenses and commercial investments.

Non-GAAP Adjusted Net Income for Q4 2025 $1.5 million. Adjustments primarily related to acquisition costs and amortization of intangible assets.

GAAP Net Income for Full Year 2025 $5.9 million. Reflects overall profitability despite acquisition-related expenses.

Non-GAAP Adjusted Net Income for Full Year 2025 $59.5 million. Adjustments include acquisition costs and amortization of intangible assets.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Tyvaso DPI: Grew from a $450 million brand in 2018 to a $1 billion franchise within 36 months of launch. It has become a $1 billion brand and is expected to deliver over $350 million in royalties over the next 36 months.

FUROSCIX: Generated $23.3 million in Q4 net sales, up 91% year-over-year, and $70.4 million for the full year 2025. The company plans to expand its market through hospital pull-through, salesforce focus, and marketing investment. The ReadyFlow Autoinjector, if approved, could expand the market and reduce costs.

Afrezza: Generated $22.3 million in Q4 U.S. sales, up 22% year-over-year, and $74.6 million globally in 2025. The company is preparing for a pediatric launch and has updated its label to improve dosing guidance. The pediatric opportunity could represent a significant revenue opportunity, with potential share in the range of 23%-37%.

Nintedanib DPI: Progressing into Phase II trials for IPF. It aims to address unmet needs in IPF treatment by improving tolerability and efficacy through direct lung targeting.

Afrezza International Expansion: First commercial shipment to Cipla for India marks the beginning of international growth.

FUROSCIX Market Expansion: Focus on hospital discharge protocols, cardiology, nephrology, and marketing to expand its market.

Revenue Growth: Achieved $112 million in Q4 revenue, up 46% year-over-year, and $349 million for the full year 2025, representing a 22% increase.

Diversification: Transitioned from a single revenue stream to a diversified portfolio with 4 FDA-approved products.

Salesforce Expansion: Increased salesforce from 80 to 160 reps to support FUROSCIX and other products.

Pipeline Investment: Investing in MannKind 201 and other programs with blockbuster potential.

Strategic Acquisitions: Acquired sCPharmaceuticals to strengthen the cardiometabolic franchise.

Long-term Supply Agreement: Amended agreement with United Therapeutics to ensure predictable revenue through 2031.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Regulatory Risks: The company has two important PDUFA dates coming up for Afrezza pediatric indication and Furoscix ReadyFlow Autoinjector. Delays or negative outcomes in these regulatory approvals could impact growth projections and strategic plans.

Competitive Pressures: Competition in the PAH market is evolving, with potential alternative delivery formats and softness inhalers posing a threat to Tyvaso DPI's market share. This could impact royalty revenues and overall financial performance.

Supply Chain and Manufacturing Risks: The company is preparing its Danbury facility to scale development programs, but any disruptions or inefficiencies in manufacturing could affect product availability and revenue generation.

Economic Sensitivity: Q1 is typically soft for FUROSCIX due to deductible resets and higher out-of-pocket costs for patients, particularly Medicare patients. This economic sensitivity could impact quarterly revenue performance.

Integration and Workforce Risks: The acquisition of sCPharmaceuticals and the doubling of the salesforce to 160 reps could pose integration challenges and risks of turnover, which may affect sales performance and operational efficiency.

Product Adoption Challenges: The success of new products like the Furoscix ReadyFlow Autoinjector and Afrezza pediatric indication depends on market adoption. Resistance from healthcare providers or patients could limit growth potential.

Pipeline Development Risks: The MannKind 201 program and other pipeline initiatives are in early stages. Delays or failures in clinical trials could hinder long-term growth and strategic objectives.

Financial Risks: The company plans to invest up to an additional $40 million in commercial spend for product launches. If these investments do not yield expected returns, it could strain financial resources.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Revenue Projections: The company expects a revenue run rate of over $450 million in 2026, driven by growth in Afrezza, FUROSCIX, and Tyvaso DPI.

Afrezza Growth: Afrezza is positioned for growth with the potential pediatric approval in 2026. The company plans to increase commercial investments to support this growth.

FUROSCIX Growth: FUROSCIX is expected to achieve a CVR range of $110 million to $120 million in 2026. The company is investing in hospital pull-through, salesforce focus, and marketing to accelerate growth.

Tyvaso DPI Performance: United Therapeutics expects durable double-digit growth of Tyvaso DPI in 2026, which will contribute to MannKind's royalty revenue.

Nintedanib DPI Development: The company anticipates enrolling the first patient in the global Phase II study for Nintedanib DPI in the next quarter, with top-line data expected in the second half of 2026. This program is seen as having blockbuster potential.

Product Launches: The company is preparing for multiple product launches in 2026, including the Afrezza pediatric indication and the FUROSCIX ReadyFlow Autoinjector.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:How is the $350 million number expected to evolve over the next 36 months, and what is the annual minimum supply agreement with UT?

A:The $350 million number is tied to a volume-based agreement. For 2025, the amount is approximately $100 million, which will remain consistent for the next two years. After that, the minimum quantities will be about half, approximately $50 million annually for the out years.

Q:What is the strategic priority of the MNKD-201 program, and when will Phase Ib data be available?

A:MNKD-201 is a critical priority with significant resources allocated. Phase Ib is a two-part study with 12 patients in each part. Part 1 is expected to wrap up in the next month, and Part 2 will follow in Q2. Data from the study, focusing on tolerability and FEV1 changes, is expected in the second half of the year.

Q:Can the UT supply contracts for DPI be updated in future years, and what are the tailwinds for future revenue growth from Afrezza and FUROSCIX?

A:The UT supply contracts can be modified if both parties agree. Tailwinds for revenue growth include the pediatric safety and efficacy approval for Afrezza, expected to drive growth in Q3 and Q4, and the launch of the FUROSCIX auto-injector in July, which is expected to transform the patient and caregiver experience.

Q:How should gross and operating margins evolve over 2026 with FUROSCIX and Afrezza?

A:Gross margins may slightly decline initially due to the on-body infuser's lower margin compared to Afrezza. However, margins are expected to improve significantly with the launch of the FUROSCIX auto-injector. Intangible assets related to these products will also impact margins due to amortization.

Q:How does MannKind leverage FDKP for drug delivery, and how has this evolved in PAH, PH-ILD, and IPF?

A:FDKP is critical for delivering drugs deep into the lungs with consistent penetration. It protects and shapes the molecule for effective delivery. This technology is used in Afrezza and other pipeline products, providing a competitive advantage and scalability for MannKind.

Q:What is the market opportunity for Afrezza in the pediatric segment, and will there be a bolus of switch patients?

A:Recent market research indicates a large opportunity in the pediatric segment, including naive patients. The initial launch will focus on switching patients, with a methodical approach targeting key centers and community sales forces. A bolus of switch patients is expected initially, but consumer advertising will be gradual.

Q:What is the status of the second molecule (1505) collaboration with UT?

A:The collaboration is progressing well, with the first part of the program nearing completion. The molecule has blockbuster potential, but its future direction depends on UT's decisions.

Q:Review of Unclear Management Responses

A:Management avoided providing specific details on the quantities and dollar amounts of the UT supply agreement, citing redacted information in the 10-K. Additionally, while discussing the second molecule (1505) collaboration with UT, management did not provide concrete timelines or commitments, leaving the decision to UT.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

MNKD Transcript

MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript

Positive2-26

MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

Positive11-5

The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Neutral9-10

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Neutral9-7

MNKD Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.